SEARCH RESULTS

3 RESULTS

Norman Relkin on Gammagard™ Misses Endpoints in Phase 3 Trial

COMMENT The topline results were announced today to satisfy SEC requirements and Baxter's obligation to its investors to report material findings in a timely fashion. However, analysis of data from the GAP study is very much ongoing. It is too soon to talk ...

Norman Relkin on Quick-and-Early IVIG Therapy: Hints of Promise

COMMENT First off, I’d like to disclose that I am lead investigator in the GAP 160701 Study, which is the NIA- and Baxter-supported Phase 3 pivotal study of Gammagard® IVIG in AD that has been conducted at 45 ADCS sites in the U.S. and Canada. It employed a ...

Current Filters

  • TYPE: Comment x
  • Commentator: Relkin, Norman x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE